Contemporary Oncology (Feb 2024)
High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial
- Rafal Dziadziuszko,
- Nir Peled,
- Tony Mok,
- Solange Peters,
- Santiago Ponce Aix,
- Jorge Alatorre-Alexander,
- Brian D. Vicuna,
- Margaret Maclennan,
- Vijay Bhagawati-Prasad,
- Sarah M. Shagan,
- Erica Schleifman,
- Thorsten Ruf,
- Michael S. Mathisen,
- Shirish M. Gadgeel
Affiliations
- Rafal Dziadziuszko
- Nir Peled
- Tony Mok
- Solange Peters
- Santiago Ponce Aix
- Jorge Alatorre-Alexander
- Brian D. Vicuna
- Margaret Maclennan
- Vijay Bhagawati-Prasad
- Sarah M. Shagan
- Erica Schleifman
- Thorsten Ruf
- Michael S. Mathisen
- Shirish M. Gadgeel
- DOI
- https://doi.org/10.5114/wo.2023.135246
- Journal volume & issue
-
Vol. 27,
no. 4
pp. 217 – 223
Abstract
No abstracts available.Keywords
- alectinib
- blood-based assay
- blood first assay screening trial (bfast)
- non small cell lung cancer
- nsclc
- ret fusion
- ctdna
- circulating tumour dna
- liquid biopsy
- ngs